ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
+13.07%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$246M
AUM Growth
+$246M
(-20%)
Cap. Flow
-$65.7M
Cap. Flow
% of AUM
-26.67%
Top 10 Holdings %
Top 10 Hldgs %
67.39%
Holding
78
New
29
Increased
8
Reduced
16
Closed
23
Top Buys
| 1 |
Merck
MRK
|
$14M |
| 2 |
Centene
CNC
|
$13.8M |
| 3 |
Sabra Healthcare REIT
SBRA
|
$5.43M |
| 4 |
Cigna
CI
|
$5.16M |
| 5 |
Elevance Health
ELV
|
$4.96M |
Top Sells
| 1 |
Humana
HUM
|
$15.9M |
| 2 |
Takeda Pharmaceutical
TAK
|
$14.3M |
| 3 |
Qiagen
QGEN
|
$13.1M |
| 4 |
Eli Lilly
LLY
|
$12.4M |
| 5 |
Baxter International
BAX
|
$11.9M |
Sector Composition
| 1 | Healthcare | 73.98% |
| 2 | Real Estate | 2.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Labcorp
LH
$23.1B
| $21.4M | 8.69% | 90,924 -6,321 | -7% | -$1.49M |
|
|
2
Cigna
CI
$80.3B
| $16.5M | 6.68% | 49,678 +15,579 | +46% | +$5.16M |
|
|
3
Merck
MRK
$210B
| $14M | 5.68% | +126,003 | New | +$14M |
|
|
4
Centene
CNC
$14.3B
| $13.8M | 5.61% | +168,363 | New | +$13.8M |
|
|
5
Elevance Health
ELV
$71.8B
| $13.4M | 5.43% | 26,077 +9,675 | +59% | +$4.96M |
|
6
Icon
ICLR
$13.8B
| $11.4M | 4.65% | 58,896 -7,541 | -11% | -$1.46M |
|
7
AstraZeneca
AZN
$248B
| $9.59M | 3.89% | 141,420 +40,372 | +40% | +$2.74M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $8.73M | 3.55% | 84,357 -61,017 | -42% | -$6.31M |
|
|
9
Sabra Healthcare REIT
SBRA
$4.58B
| $5.43M | 2.2% | +436,524 | New | +$5.43M |
|
10
Elutia
ELUT
$96.7M
| $5.35M | 2.17% | 1,259,544 +119,612 | +10% | +$508K |
|
11
Insmed
INSM
$28.8B
| $4.86M | 1.97% | 243,122 +135,409 | +126% | +$2.71M |
|
|
ALBO
12
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $4.69M | 1.91% | 217,209 +44,588 | +26% | +$964K |
|
13
Encompass Health
EHC
$12.3B
| $4.67M | 1.9% | 78,144 -4,785 | -6% | -$286K |
|
14
Cartesian Therapeutics
RNAC
$261M
| $4.27M | 1.73% | 3,777,618 -160,791 | -4% | -$182K |
|
15
Viking Therapeutics
VKTX
$3.04B
| $4.07M | 1.65% | +433,035 | New | +$4.07M |
|
16
Cencora
COR
$56.5B
| $3.49M | 1.42% | +21,034 | New | +$3.49M |
|
17
BioNTech
BNTX
$24B
| $3.25M | 1.32% | +21,664 | New | +$3.25M |
|
18
Ocular Therapeutix
OCUL
$2.12B
| $2.99M | 1.21% | 1,063,953 -342 | -0% | -$961 |
|
|
ADAP
19
Adaptimmune Therapeutics
ADAP
$15.6M
| $2.53M | 1.03% | 1,733,236 -55,281 | -3% | -$80.7K |
|
20
Zoetis
ZTS
$69.3B
| $2.45M | 1% | 16,728 -27,558 | -62% | -$4.04M |
|
21
Sutro Biopharma
STRO
$72.7M
| $2.28M | 0.92% | 281,895 +15,216 | +6% | +$123K |
|
|
22
Qiagen
QGEN
$10.1B
| $2.03M | 0.83% | 40,749 -263,179 | -87% | -$13.1M |
|
23
Tenet Healthcare
THC
$16.3B
| $1.97M | 0.8% | 40,452 -30,083 | -43% | -$1.47M |
|
24
Becton Dickinson
BDX
$55.3B
| $1.72M | 0.7% | 6,761 -27,521 | -80% | -$7M |
|
25
Bio-Rad Laboratories Class A
BIO
$8.06B
| $1.64M | 0.66% | 3,893 -3,091 | -44% | -$1.3M |
|